Next Article in Journal
Erratum: Mangiatordi, G.F., et al. Human Aquaporin-4 and Molecular Modeling: Historical Perspective and View to the Future. Int. J. Mol. Sci. 2016, 17, 1119
Next Article in Special Issue
Expression, Purification, and Biophysical Characterization of a Secreted Anthrax Decoy Fusion Protein in Nicotiana benthamiana
Previous Article in Journal
Panax ginseng Fraction F3 Extracted by Supercritical Carbon Dioxide Protects against Oxidative Stress in ARPE-19 Cells
Previous Article in Special Issue
Direct LAMP Assay without Prior DNA Purification for Sex Determination of Papaya
Open AccessReview

The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B

1
School of Biological Sciences & Technology, Chonnam National University, Gwangju 61186, Korea
2
Molecular Biofarming Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon 34141, Korea
*
Author to whom correspondence should be addressed.
Academic Editor: Chang Won Choi
Int. J. Mol. Sci. 2016, 17(10), 1715; https://doi.org/10.3390/ijms17101715
Received: 26 August 2016 / Revised: 23 September 2016 / Accepted: 29 September 2016 / Published: 13 October 2016
(This article belongs to the Special Issue Plant-Derived Pharmaceuticals by Molecular Farming 2016)
Disease prevention through vaccination is considered to be the greatest contribution to public health over the past century. Every year more than 100 million children are vaccinated with the standard World Health Organization (WHO)-recommended vaccines including hepatitis B (HepB). HepB is the most serious type of liver infection caused by the hepatitis B virus (HBV), however, it can be prevented by currently available recombinant vaccine, which has an excellent record of safety and effectiveness. To date, recombinant vaccines are produced in many systems of bacteria, yeast, insect, and mammalian and plant cells. Among these platforms, the use of plant cells has received considerable attention in terms of intrinsic safety, scalability, and appropriate modification of target proteins. Research groups worldwide have attempted to develop more efficacious plant-derived vaccines for over 30 diseases, most frequently HepB and influenza. More inspiring, approximately 12 plant-made antigens have already been tested in clinical trials, with successful outcomes. In this study, the latest information from the last 10 years on plant-derived antigens, especially hepatitis B surface antigen, approaches are reviewed and breakthroughs regarding the weak points are also discussed. View Full-Text
Keywords: antigen; hepatitis B virus; plant edible vaccine; recombinant protein; molecular farming; virus-like particles antigen; hepatitis B virus; plant edible vaccine; recombinant protein; molecular farming; virus-like particles
Show Figures

Graphical abstract

MDPI and ACS Style

Joung, Y.H.; Park, S.H.; Moon, K.-B.; Jeon, J.-H.; Cho, H.-S.; Kim, H.-S. The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B. Int. J. Mol. Sci. 2016, 17, 1715.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop